Good Day BIO Newsletter

We have details on BIO’s comments on a U.S. Patent and Trademark Office proposal that would harm the patent system—plus, more groundbreaking companies featured at the NIH Innovation Zone at BIO 2024 and how to nominate a leader for the California Life Sciences Pantheon Awards. Don’t forget to take our reader survey! (623 words, 3 minutes, 6 seconds)

At long last, the FTC released an interim report on PBMs—and the findings are not surprising. We have details, plus more about the winners of BIO’s 2024 Agri-Biotechnology Awards. Don’t forget to take our reader survey! (523 words, 2 minutes, 36 seconds)

Today, we have news on Boehringer Ingelheim’s new biomass power plant and the expanding range of lone star ticks—plus, how you can weigh in on what’s next for BIO’s communications products. (731 words, 3 minutes, 39 seconds)

Congress heads back to work, and we catch up on news including the FDA’s approval of Eli Lilly’s Alzheimer’s drug and what happened at the U.S.-Mexico-Canada Agreement dispute panel on Mexico’s biotech corn ban. (618 words, 3 minutes, 5 seconds)We want your feedback! We are conducting a survey to get reader feedback on the Good Day BIO newsletter and ensure our content best meets your needs. Click here to take our short survey.

Before we head out for the holiday week, we have more on the CDC’s new recommendations for respiratory diseases, a new analysis of the Inflation Reduction Act’s impacts, and a look at two biotech innovators to watch. (659 words, 3 minutes, 17 seconds)We’re taking a publishing break for the July 4 holiday week. We will return on Monday, July 8. In the meantime, keep an eye on Bio.News for breaking news.

Eli Lilly teams up with OpenAI to fight AMR—another way AI could transform biotech. Plus, dengue is surging worldwide, and the CDC says it now threatens the U.S.—but biotech and One Health could help. (512 words, 2 minutes, 33 seconds)

BIO President & CEO John F. Crowley explored the meaning of “innovation, access, and advocacy” at the American Cancer Society Cancer Action Network breakfast yesterday—we have a recap, plus how caregivers are helping researchers find ALS biomarkers. (598 words, 2 minutes, 59 seconds)

A recent WHO report says the pipeline for antibacterials is insufficient to meet the threat of antimicrobial resistance. Meanwhile, the panel deciding whether Mexico’s plan to ban biotech corn violates the U.S.-Mexico-Canada trade agreement is expected to meet this week. (605 words, 3 minutes, 1 second)

The end of last week brought progress on reauthorizing the Pediatric Priority Review Voucher (PPRV) program, and the New York Times turned up the heat on PBMs. (574 words, 2 minutes, 52 seconds)

We launch our new series highlighting companies supported by the NIH SEED program at the NIH Innovation Zone at BIO 2024—today, meet a company using AI to help clinicians assess the effectiveness of neurological and psychiatric therapies. Plus, BIO joins the SAF Coalition and a lot more news. (604 words, 3 minutes, 1 second)